Immunotherapy and chemoradiation for elderly esophageal cancer patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older.
- You have esophageal squamous cell carcinoma that cannot be removed with surgery or you choose not to have surgery.
- You have not had radiation therapy to your chest before.
- You do not have an active autoimmune disease or a history of one.
- You do not have active infections like hepatitis B or C, HIV, or tuberculosis.
- You have not had another cancer (except for some skin cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study compares two standard approaches for treating esophageal cancer before surgery: chemotherapy combined with radiation versus chemotherapy combined with immunotherapy. The goal is to see which approach works better for shrinking tumors and improving outcomes in patients whose cancer is considered removable.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests combining chemoradiation with the immunotherapy drug iparomlimab for adults aged 70 and older with advanced esophageal cancer. The goal is to see if adding immunotherapy after standard chemoradiation improves outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.